A 70-year-old man presented to Tufts emergency department with a 2-day history of left eye redness and periorbital swelling ...

Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for ...

“In people who have diabetes, when they’re on GLP-1s, they experience an early increase in the risk of diabetic retinopathy,” ...

OCT has transformed retinal practice, enhancing diagnostic accuracy and treatment efficiency while reducing reliance on ...

As Ghana joins the global community in observing Diabetic Eye Disease Awareness Month this November, a sobering reality ...

Diabetic retinopathy, a leading cause of blindness in working-age adults, silently damages eyes through high blood sugar.

In this video from the American Academy of Ophthalmology meeting, Diana V. Do, MD, discusses the real-world use of aflibercept 8 mg in wet age-related macular degeneration or diabetic macular edema.

LightPath Technologies is on the path of hypergrowth and could see its stock price rise by 50% within the next few quarters.

D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of ...

Otsuka Pharma enters licensing agreement with 4D Molecular Therapeutics for ophthalmic gene therapy drug candidate, 4D-150: Tokyo Monday, November 3, 2025, 11:00 Hrs [IST] Otsuka ...

4D Molecular Therapeutics (4DMT) released positive interim 1.5- to 3.5-year data from the phase 1/2 PRISM clinical trial ...

India currently has an estimated 10.1 crore people with diabetes, of whom about 1.26 crore are believed to have eye-related complications and nearly 40 lakh face the danger of irreversible blindness.